Gemphire Therapeutics Inc.
(NASDAQ : GEMP)

( )
GEMP After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
-0.40%42.160.9%$944.32m
JNJJohnson & Johnson
-1.14%135.320.6%$831.62m
MRKMerck & Co., Inc.
-1.43%69.170.6%$633.99m
ABBVAbbVie, Inc.
0.10%97.732.1%$629.84m
LLYEli Lilly and Company
-0.69%105.091.0%$472.84m
BMYBristol-Myers Squibb Company
-0.41%60.071.4%$402.76m
AZNAstraZeneca PLC Sponsored ADR
-0.23%38.761.3%$188.11m
NVSNovartis AG Sponsored ADR
0.29%83.800.2%$141.82m
GSKGlaxoSmithKline plc Sponsored ADR
0.41%41.500.2%$114.74m
SNYSanofi Sponsored ADR
1.52%42.860.2%$100.50m
NVONovo Nordisk A/S Sponsored ADR Class B
2.01%49.180.1%$76.18m
LCILannett Company, Inc.
5.61%5.6537.9%$9.29m
AKTXAkari Therapeutics Plc Sponsored ADR
-1.56%1.891.7%$0.05m
EPIXESSA Pharma Inc
4.26%3.180.0%$0.01m

Company Profile

Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the provision of treatment options for cardiometabolic diseases including dyslipidemia and NASH. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI.